Ciena Corporation (NYSE:CIEN) expects to announce results for its fiscal second quarter ended May 3, 2014 on Thursday, June 5, 2014 before the open of the financial markets. The press release also will be available on Ciena’s website at www.ciena.com. Ciena Corporation (NYSE:CIEN) net profit margin is -2.50% and weekly performance is -0.47%. On last trading day company shares ended up $19.24. Analysts mean target price for the company is $27.99. Ciena Corporation (NYSE:CIEN) distance from 50-day simple moving average (SMA50) is -9.13%.
Juniper Networks Inc (NYSE:JNPR), the industry leader in network innovation, announced the Company will be hosting its 2014 Annual Meeting of Stockholders on Wednesday, May 21, 2014 at 9:00 a.m. Pacific Daylight Time (PDT)/12:00 p.m. Eastern Daylight Time (EDT) at its offices located at 1133 Innovation Way, Building A, in Sunnyvale, Calif. Juniper Networks, Inc. (NYSE:JNPR) shares advanced 0.86% in last trading session and ended the day on $24.62. Gross Margin is 62.60% and its return on assets is 4.60%. Juniper Networks, Inc. (NYSE:JNPR) quarterly performance is -10.34 %.
Calix Inc (NASDAQ:CALX) has received an average recommendation of “Hold” from the ten ratings firms that are currently covering the stock,AnalystRatingsNetwork.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $12.13. Calix Inc (NYSE:CALX) shares moved up 3.43% in last trading session and was closed at $8.14, while trading in range of $7.81 – $8.15. Calix Inc (NYSE:CALX) year to date (YTD) performance is -15.56%.
E F G EUROBANK ERGAS (OTCMKTS:EGFEY) ended the last trading day at $0.228 .
Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) announced the appointment of Russell J. Cox to the newly created position of chief operating officer (COO). Mr. Cox, who joined Jazz Pharmaceuticals in July 2010, most recently served as executive vice president and chief commercial officer at the company. He will continue to report to Bruce Cozadd, chairman and chief executive officer, and will now have global responsibility for the commercial, research and development (R&D) and technical operations organizations. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) net profit margin is 24.80% and weekly performance is 0.92%. On last trading day company shares ended up $131.43. Analysts mean target price for the company is $177.07. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) distance from 50-day simple moving average (SMA50) is -5.00%.